Against the constant reminder that sugar operates in a bear market, and diversification is imperative for sugar companies to cushion them against volatility, very few have tipped their toes in the maturing bioeconomy promising rich rewards in the high-value-low-volume sector. Investment in synthetic biology platforms has been US$9 bln in Q1 and Q2 20211. The four process conversion technologies supporting the biotech sector are biochemical – enzyme-based via fermentation; thermochemical; hybrid of thermochemical and biochemical; and chemical – mediated by a proprietary catalyst. Of these, the biochemical platform continues to maintain ascendancy as the metabolic engineering toolbox makes significant leaps… Login to continue
Login or sign up
Trends in biobased products R&D and new build activity in 2021 [Registered]
Against the constant reminder that sugar operates in a bear market, and diversification is imperative for sugar companies to cushion them against volatility, very few have tipped their toes in the maturing bioeconomy promising rich rewards in the high-value-low-volume sector. Investment in synthetic biology platforms has been US$9 bln in Q1 and Q2 20211. The four process conversion technologies supporting the biotech sector are biochemical – enzyme-based via fermentation; thermochemical; hybrid of thermochemical and biochemical; and chemical – mediated by a proprietary catalyst. Of these, the biochemical platform continues to maintain ascendancy as the metabolic engineering toolbox makes significant leaps… Login to continue
Login or sign up
Similar stories you might like
Monthly Snapshot January [Full subscriber]
Fumaric Acid [Full subscriber]